Femasys (FEMY) Q4 2024 earnings summary

Executive summary

• Achieved major regulatory and commercial milestones for FemBloc and FemaSeed, including European approval and new distribution partnerships in Spain, UK, and Israel.

• Peer-reviewed publications confirmed positive safety and efficacy for FemBloc and FemaSeed clinical trials.

• Strategic partnerships established with leading fertility networks to expand FemaSeed's reach.

Financial highlights

• Sales rose 52.0% year-over-year to $1,629,108 in 2024 from $1,071,970 in 2023.

• Research and development expenses increased 14.0% to $8,216,543 in 2024.

• Net loss widened to $18,816,628, or ($0.85) per share, compared to $14,247,124, or ($0.93) per share, in 2023.

• Cash and cash equivalents at year-end were $3.5 million, with an accumulated deficit of $127.2 million.

Outlook and guidance

• U.S. revenue for FemaSeed expected to increase by approximately 50% in Q1 2025 versus Q4 2024.

• Sufficient cash, including $5.4 million raised post-year-end, to fund operations into Q3 2025.

• Anticipates CE mark approval for FemBloc polymer in Europe by mid-2025; U.S. pivotal trial for FemBloc ongoing.